Luminex
Diasorin Nabs FDA 510(k) Clearance for Expanded Respiratory Panel
The firm said that its NxTag Respiratory Pathogen Panel v2 adds detection of the SARS-CoV-2 virus for a total of 21 viral and bacterial targets.
Long COVID Markers Found Using Multiomic Methods
With proteomic, metabolomic, and cytokine profiling of blood plasma samples, researchers saw distinct disease clusters and markers for the condition.
Streck Quality Controls for DiaSorin's Luminex Sepsis Tests Receive FDA Clearance
The quality controls are designed to verify the performance of the Luminex Verigene Blood Culture Gram-Positive and Gram-Negative tests.
Decline in DiaSorin's Q2 MDx Revenues Offset by Strength in Immunodiagnostics
Non-COVID-19 immunodiagnostics revenues drove an otherwise strong quarter for DiaSorin with continued growth in North America and Europe and slow improvement in China.
DiaSorin Q1 Revenues Fall 19 Percent on COVID Sales Decline
A 78 percent decline in COVID testing revenues was partially offset by revenue growth in its other diagnostics businesses.
Mar 27, 2023
DiaSorin 2022 Revenues Grow 10 Percent
Apr 13, 2021
Apr 12, 2021